The medication Farxiga is a selective sglt2 inhibitor used to treat type 2 diabetes mellitus. It works by blocking the sodium glucose cotransporter 2 in the proximal renal tubule which reduces glucose reabsorption and promotes urinary glucose excretion. This mechanism lowers blood glucose levels without stimulating insulin secretion and provides additional cardiovascular benefits in patients with chronic kidney disease. The therapeutic role of Farxiga also includes risk reduction for hospitalization due to heart failure and slowing the progression of diabetic nephropathy. Pharmacologically the drug is absorbed orally, distributed systemically and eliminated primarily through renal excretion after metabolism by cyp2c8 and cyp3a4 enzymes. In the body the inhibition of sglt2 leads to decreased tubular glucose reabsorption resulting in natriuresis and improved glycemic control.

Farxiga is a medication that improves blood sugar control in adults with type 2 diabetes mellitus. Its pharmacological action involves selective inhibition of the sodium-glucose cotransporter-2 in the renal proximal tubule. By blocking this transporter the drug promotes urinary glucose excretion and lowers circulating glucose levels. Clinically this reduction in glucose leads to modest but consistent improvements in glycemic parameters and cardiovascular outcomes. The medication also reduces the risk of heart failure hospitalization in patients with chronic kidney disease. Overall the drug's mechanism relies on increasing filtered glucose removal, which indirectly decreases insulin demand and improves metabolic health.

The most common side effects include mild headache, temporary fatigue, and occasional nausea. Some individuals report mild dizziness or a feeling of lightheadedness after the first dose. A small number experience mild skin irritation at the injection site without any lasting damage. Mild muscle aches or joint discomfort can occur but usually resolve within a day or two. Transient fever or chills may appear as a short-lived immune response. These reactions are generally self-limiting and do not require medical intervention. Most side effects are mild to moderate and fade as the body adapts.

Headache is frequently reported in patients taking certain medications. Nausea often appears alongside the initial doses and may persist for a short time. Drowsiness can occur, especially when the drug affects central nervous system pathways. Dizziness may be experienced as a sensation of light-headedness during the early phase of treatment. Dry mouth is a common complaint that results from reduced salivary secretion. Skin reactions such as mild rashes may develop in some individuals. Fatigue often accompanies these effects and tends to improve with continued use.